CAM
TEVA icon

CMT Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

CMT Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-30,000
Closed -$240K – 114
2017
Q3 		$240K Buy
+30,000
New +$675K 0.01% 155

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

CMT Asset Management's TEVA Position: Q4 2017 in Review

CMT Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 30,000 shares — an estimated $240K sold.

CMT Asset Management first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $240K in Q3 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • CMT Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • CMT Asset Management sold 30,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $240K.
  • CMT Asset Management first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • CMT Asset Management's Teva Pharmaceuticals position peaked at $240K in Q3 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on CMT Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.